Opinion|Videos|December 19, 2023
IsKia: Isa-KRd vs KRd as Pre-Transplant Induction and Post-Transplant Consolidation in NDMM
Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
4
Durability of PFS and OS Benefit vs. Historical Control
5